schliessen

Filtern

 

Bibliotheken

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Aims/hypothesis The EFFECT-II study aimed to investigate the effects of dapagliflozin and omega-3 ( n -3) carboxylic acids (OM-3CA), individually or combined, on liver fat content in individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Methods This randomised placebo-contr... Full description

Journal Title: Diabetologia 2018-07-03, Vol.61 (9), p.1923-1934
Main Author: Eriksson, Jan W
Other Authors: Lundkvist, Per , Jansson, Per-Anders , Johansson, Lars , Kvarnström, Mats , Moris, Linda , Miliotis, Tasso , Forsberg, Gun-Britt , Risérus, Ulf , Lind, Lars , Oscarsson, Jan
Format: Electronic Article Electronic Article
Language: English
Subjects:
Non
Publisher: Berlin/Heidelberg: Springer Berlin Heidelberg
ID: ISSN: 0012-186X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_swepub_primary_oai_gup_ub_gu_se_269679
title: Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
format: Article
creator:
  • Eriksson, Jan W
  • Lundkvist, Per
  • Jansson, Per-Anders
  • Johansson, Lars
  • Kvarnström, Mats
  • Moris, Linda
  • Miliotis, Tasso
  • Forsberg, Gun-Britt
  • Risérus, Ulf
  • Lind, Lars
  • Oscarsson, Jan
subjects:
  • 3 fatty acids
  • adaptation
  • Aged
  • Alanine
  • Alanine transaminase
  • alcoholic fatty liver disease
  • Analysis
  • Article
  • Aspartate aminotransferase
  • Benzhydryl Compounds - administration & dosage
  • Biomarkers
  • Biomarkers - metabolism
  • Body weight
  • Carboxylic acids
  • Carboxylic Acids - administration & dosage
  • Clinical Medicine
  • Clinical trials
  • controlled-trial
  • Cytokeratin
  • Dapagliflozin
  • Diabetes
  • Diabetes mellitus
  • Diabetes mellitus (non-insulin dependent)
  • Diabetes Mellitus, Type 2 - complications
  • Diabetes Mellitus, Type 2 - drug therapy
  • Diabetes therapy
  • Docosahexaenoic acid
  • Double-Blind Method
  • Drug Therapy, Combination
  • Eicosapentaenoic acid
  • Endocrinology
  • Endocrinology & Metabolism
  • Endocrinology and Diabetes
  • Endokrinologi och diabetes
  • Fatty Acids - metabolism
  • Fatty liver
  • Female
  • Fibroblast growth factor
  • fish-oil
  • glucose
  • Glucose - metabolism
  • Glucosides - administration & dosage
  • growth-factor 21
  • Hepatocytes - metabolism
  • Human Physiology
  • Humans
  • Inflammation
  • insulin sensitivity
  • Internal Medicine
  • Klinisk medicin
  • Lipid Metabolism
  • Liver diseases
  • Liver Function Tests
  • Liver steatosis
  • Magnetic Resonance Imaging
  • Male
  • Medical and Health Sciences
  • Medicin och hälsovetenskap
  • Medicine
  • Medicine & Public Health
  • Metabolic Diseases
  • Middle Aged
  • Non
  • Non-alcoholic fatty liver
  • Non-alcoholic fatty liver disease
  • Non-alcoholic Fatty Liver Disease - complications
  • Non-alcoholic Fatty Liver Disease - drug therapy
  • Omega
  • Omega-3 fatty acids
  • Organic acids
  • oxidation
  • Oxidative Stress
  • pnpla3
  • Proton density fat fraction
  • resistance
  • steatohepatitis
  • Sweden
  • Type 2 diabetes
  • Unsaturated fatty acids
ispartof: Diabetologia, 2018-07-03, Vol.61 (9), p.1923-1934
description: Aims/hypothesis The EFFECT-II study aimed to investigate the effects of dapagliflozin and omega-3 ( n -3) carboxylic acids (OM-3CA), individually or combined, on liver fat content in individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Methods This randomised placebo-controlled double-blind parallel-group study was performed at five clinical research centres at university hospitals in Sweden. 84 participants with type 2 diabetes and NAFLD were randomly assigned 1:1:1:1 to four treatments by a centralised randomisation system, and all participants as well as investigators and staff involved in the study conduct and analyses were blinded to treatments. Each group received oral doses of one of the following: 10 mg dapagliflozin ( n  = 21), 4 g OM-3CA ( n  = 20), a combination of both ( n  = 22) or placebo ( n  = 21). The primary endpoint was liver fat content assessed by MRI (proton density fat fraction [PDFF]) and, in addition, total liver volume and markers of glucose and lipid metabolism as well as of hepatocyte injury and oxidative stress were assessed at baseline and after 12 weeks of treatment (completion of the trial). Results Participants had a mean age of 65.5 years (SD 5.9), BMI 31.2 kg/m 2 (3.5) and liver PDFF 18% (9.3). All active treatments significantly reduced liver PDFF from baseline, relative changes: OM-3CA, −15%; dapagliflozin, −13%; OM-3CA + dapagliflozin, −21%. Only the combination treatment reduced liver PDFF ( p  = 0.046) and total liver fat volume (relative change, −24%, p =  0.037) in comparison with placebo. There was an interaction between the PNPLA3 I148M polymorphism and change in liver PDFF in the active treatment groups ( p =  0.03). Dapagliflozin monotherapy, but not the combination with OM-3CA, reduced the levels of hepatocyte injury biomarkers, including alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase (γ-GT), cytokeratin (CK) 18-M30 and CK 18-M65 and plasma fibroblast growth factor 21 (FGF21). Changes in γ-GT correlated with changes in liver PDFF (ρ  =  0.53, p =  0.02). Dapagliflozin alone and in combination with OM-3CA improved glucose control and reduced body weight and abdominal fat volumes. Fatty acid oxidative stress biomarkers were not affected by treatments. There were no new or unexpected adverse events compared with previous studies with these treatments. Conclusions/interpretation Combined treatment with dapagliflozin and OM-3CA significantly reduced liver fat
language: eng
source:
identifier: ISSN: 0012-186X
fulltext: no_fulltext
issn:
  • 0012-186X
  • 1432-0428
  • 1432-0428
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.8228447
LOCALfalse
PrimoNMBib
record
control
sourceidgale_swepu
recordidTN_cdi_swepub_primary_oai_gup_ub_gu_se_269679
sourceformatXML
sourcesystemPC
galeidA548450521
sourcerecordidA548450521
originalsourceidFETCH-LOGICAL-1688t-69149ce4081969da7ad352bae19900595d8157fdc40dc5a0f08215818e13cc90
addsrcrecordideNp9k89u1DAQxiMEoqXwAFyQJS4cSLEd24k5VFqV8keq4FIhbpZjT1JXXjvEScvyRrwljra0bEVRDo7Gv-8be8ZTFM8JPiQY128SxoTyEpOmZKLmJX1Q7BNW0RIz2jws9pftkjTi217xJKULjHHFmXhc7FEpa8JpvV_8Ouk6MFNCsUNWD7r3rvPxpwtIB4tCWSGjxzb-2HhnkDbOZjKgEEOpvYnncQl3epo2yLtLGJF1CXQClA0GiIMHdOWmczRtBkA07-oWJkhvkUY2zq2HsvUuJxpztrjOWosGrw20sTQxTGP0PofSNNvN0-JRp32CZ9frQXH2_uTs-GN5-uXDp-PVaUlE00ylkIRJAww3RAppda1txWmrgUiJMZfcNoTXnTUMW8M17nBDCW9IA6QyRuKDotzapisY5lYNo1vrcaOidqqfB5VD_awSKCqkqBf-9b38O_d1peLYq3lWlWASk4wfbfHMrsEayJfUfke1uxPcuerjpRJYCkGWfJ-3BnGAoN0IO1obYFIWbD7oVady_5UU1ppKNxRzzahhFsuWk7arsYD8U2XDV9cnGuP3GdKkch8MeK8DxDkpigWjTArKM_ryDnoR5zHkbixULjPGrLmleu1BudDFfBGzmKoVZw3jmNOlEIf_oPJnYe1y76FzOb4jIFuBGWNKI3Q3FydYLeOgtuOg8jioZRzymQ6KF39X-0bx5_1noL5jatykJ7e8Pe38f63pdd-zaehhvK3F_aLfT64nyw
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid2063520048
display
typearticle
titleEffects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
creatorEriksson, Jan W ; Lundkvist, Per ; Jansson, Per-Anders ; Johansson, Lars ; Kvarnström, Mats ; Moris, Linda ; Miliotis, Tasso ; Forsberg, Gun-Britt ; Risérus, Ulf ; Lind, Lars ; Oscarsson, Jan
creatorcontribEriksson, Jan W ; Lundkvist, Per ; Jansson, Per-Anders ; Johansson, Lars ; Kvarnström, Mats ; Moris, Linda ; Miliotis, Tasso ; Forsberg, Gun-Britt ; Risérus, Ulf ; Lind, Lars ; Oscarsson, Jan ; Sahlgrenska akademin ; Institute of Medicine, Department of Molecular and Clinical Medicine ; Institutionen för medicin, avdelningen för molekylär och klinisk medicin ; Göteborgs universitet ; Gothenburg University ; Sahlgrenska Academy
descriptionAims/hypothesis The EFFECT-II study aimed to investigate the effects of dapagliflozin and omega-3 ( n -3) carboxylic acids (OM-3CA), individually or combined, on liver fat content in individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Methods This randomised placebo-controlled double-blind parallel-group study was performed at five clinical research centres at university hospitals in Sweden. 84 participants with type 2 diabetes and NAFLD were randomly assigned 1:1:1:1 to four treatments by a centralised randomisation system, and all participants as well as investigators and staff involved in the study conduct and analyses were blinded to treatments. Each group received oral doses of one of the following: 10 mg dapagliflozin ( n  = 21), 4 g OM-3CA ( n  = 20), a combination of both ( n  = 22) or placebo ( n  = 21). The primary endpoint was liver fat content assessed by MRI (proton density fat fraction [PDFF]) and, in addition, total liver volume and markers of glucose and lipid metabolism as well as of hepatocyte injury and oxidative stress were assessed at baseline and after 12 weeks of treatment (completion of the trial). Results Participants had a mean age of 65.5 years (SD 5.9), BMI 31.2 kg/m 2 (3.5) and liver PDFF 18% (9.3). All active treatments significantly reduced liver PDFF from baseline, relative changes: OM-3CA, −15%; dapagliflozin, −13%; OM-3CA + dapagliflozin, −21%. Only the combination treatment reduced liver PDFF ( p  = 0.046) and total liver fat volume (relative change, −24%, p =  0.037) in comparison with placebo. There was an interaction between the PNPLA3 I148M polymorphism and change in liver PDFF in the active treatment groups ( p =  0.03). Dapagliflozin monotherapy, but not the combination with OM-3CA, reduced the levels of hepatocyte injury biomarkers, including alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase (γ-GT), cytokeratin (CK) 18-M30 and CK 18-M65 and plasma fibroblast growth factor 21 (FGF21). Changes in γ-GT correlated with changes in liver PDFF (ρ  =  0.53, p =  0.02). Dapagliflozin alone and in combination with OM-3CA improved glucose control and reduced body weight and abdominal fat volumes. Fatty acid oxidative stress biomarkers were not affected by treatments. There were no new or unexpected adverse events compared with previous studies with these treatments. Conclusions/interpretation Combined treatment with dapagliflozin and OM-3CA significantly reduced liver fat content. Dapagliflozin monotherapy reduced all measured hepatocyte injury biomarkers and FGF21, suggesting a disease-modifying effect in NAFLD. Trial registration: ClinicalTrials.gov NCT02279407 Funding: The study was funded by AstraZeneca.
identifier
0ISSN: 0012-186X
1ISSN: 1432-0428
2EISSN: 1432-0428
3DOI: 10.1007/s00125-018-4675-2
4PMID: 29971527
languageeng
publisherBerlin/Heidelberg: Springer Berlin Heidelberg
subject3 fatty acids ; adaptation ; Aged ; Alanine ; Alanine transaminase ; alcoholic fatty liver disease ; Analysis ; Article ; Aspartate aminotransferase ; Benzhydryl Compounds - administration & dosage ; Biomarkers ; Biomarkers - metabolism ; Body weight ; Carboxylic acids ; Carboxylic Acids - administration & dosage ; Clinical Medicine ; Clinical trials ; controlled-trial ; Cytokeratin ; Dapagliflozin ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes therapy ; Docosahexaenoic acid ; Double-Blind Method ; Drug Therapy, Combination ; Eicosapentaenoic acid ; Endocrinology ; Endocrinology & Metabolism ; Endocrinology and Diabetes ; Endokrinologi och diabetes ; Fatty Acids - metabolism ; Fatty liver ; Female ; Fibroblast growth factor ; fish-oil ; glucose ; Glucose - metabolism ; Glucosides - administration & dosage ; growth-factor 21 ; Hepatocytes - metabolism ; Human Physiology ; Humans ; Inflammation ; insulin sensitivity ; Internal Medicine ; Klinisk medicin ; Lipid Metabolism ; Liver diseases ; Liver Function Tests ; Liver steatosis ; Magnetic Resonance Imaging ; Male ; Medical and Health Sciences ; Medicin och hälsovetenskap ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Middle Aged ; Non ; Non-alcoholic fatty liver ; Non-alcoholic fatty liver disease ; Non-alcoholic Fatty Liver Disease - complications ; Non-alcoholic Fatty Liver Disease - drug therapy ; Omega ; Omega-3 fatty acids ; Organic acids ; oxidation ; Oxidative Stress ; pnpla3 ; Proton density fat fraction ; resistance ; steatohepatitis ; Sweden ; Type 2 diabetes ; Unsaturated fatty acids
ispartofDiabetologia, 2018-07-03, Vol.61 (9), p.1923-1934
rights
0The Author(s) 2018
1COPYRIGHT 2018 Springer
2Diabetologia is a copyright of Springer, (2018). All Rights Reserved. © 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1688t-69149ce4081969da7ad352bae19900595d8157fdc40dc5a0f08215818e13cc90
citesFETCH-LOGICAL-1688t-69149ce4081969da7ad352bae19900595d8157fdc40dc5a0f08215818e13cc90
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29971527$$D View this record in MEDLINE/PubMed
1$$Uhttp://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-364901$$DView record from Swedish Publication Index
2$$Uhttps://gup.ub.gu.se/publication/269679$$DView record from Swedish Publication Index
search
creatorcontrib
0Eriksson, Jan W
1Lundkvist, Per
2Jansson, Per-Anders
3Johansson, Lars
4Kvarnström, Mats
5Moris, Linda
6Miliotis, Tasso
7Forsberg, Gun-Britt
8Risérus, Ulf
9Lind, Lars
10Oscarsson, Jan
11Sahlgrenska akademin
12Institute of Medicine, Department of Molecular and Clinical Medicine
13Institutionen för medicin, avdelningen för molekylär och klinisk medicin
14Göteborgs universitet
15Gothenburg University
16Sahlgrenska Academy
title
0Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
1Diabetologia
addtitle
0Diabetologia
1Diabetologia
descriptionAims/hypothesis The EFFECT-II study aimed to investigate the effects of dapagliflozin and omega-3 ( n -3) carboxylic acids (OM-3CA), individually or combined, on liver fat content in individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Methods This randomised placebo-controlled double-blind parallel-group study was performed at five clinical research centres at university hospitals in Sweden. 84 participants with type 2 diabetes and NAFLD were randomly assigned 1:1:1:1 to four treatments by a centralised randomisation system, and all participants as well as investigators and staff involved in the study conduct and analyses were blinded to treatments. Each group received oral doses of one of the following: 10 mg dapagliflozin ( n  = 21), 4 g OM-3CA ( n  = 20), a combination of both ( n  = 22) or placebo ( n  = 21). The primary endpoint was liver fat content assessed by MRI (proton density fat fraction [PDFF]) and, in addition, total liver volume and markers of glucose and lipid metabolism as well as of hepatocyte injury and oxidative stress were assessed at baseline and after 12 weeks of treatment (completion of the trial). Results Participants had a mean age of 65.5 years (SD 5.9), BMI 31.2 kg/m 2 (3.5) and liver PDFF 18% (9.3). All active treatments significantly reduced liver PDFF from baseline, relative changes: OM-3CA, −15%; dapagliflozin, −13%; OM-3CA + dapagliflozin, −21%. Only the combination treatment reduced liver PDFF ( p  = 0.046) and total liver fat volume (relative change, −24%, p =  0.037) in comparison with placebo. There was an interaction between the PNPLA3 I148M polymorphism and change in liver PDFF in the active treatment groups ( p =  0.03). Dapagliflozin monotherapy, but not the combination with OM-3CA, reduced the levels of hepatocyte injury biomarkers, including alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase (γ-GT), cytokeratin (CK) 18-M30 and CK 18-M65 and plasma fibroblast growth factor 21 (FGF21). Changes in γ-GT correlated with changes in liver PDFF (ρ  =  0.53, p =  0.02). Dapagliflozin alone and in combination with OM-3CA improved glucose control and reduced body weight and abdominal fat volumes. Fatty acid oxidative stress biomarkers were not affected by treatments. There were no new or unexpected adverse events compared with previous studies with these treatments. Conclusions/interpretation Combined treatment with dapagliflozin and OM-3CA significantly reduced liver fat content. Dapagliflozin monotherapy reduced all measured hepatocyte injury biomarkers and FGF21, suggesting a disease-modifying effect in NAFLD. Trial registration: ClinicalTrials.gov NCT02279407 Funding: The study was funded by AstraZeneca.
subject
03 fatty acids
1adaptation
2Aged
3Alanine
4Alanine transaminase
5alcoholic fatty liver disease
6Analysis
7Article
8Aspartate aminotransferase
9Benzhydryl Compounds - administration & dosage
10Biomarkers
11Biomarkers - metabolism
12Body weight
13Carboxylic acids
14Carboxylic Acids - administration & dosage
15Clinical Medicine
16Clinical trials
17controlled-trial
18Cytokeratin
19Dapagliflozin
20Diabetes
21Diabetes mellitus
22Diabetes mellitus (non-insulin dependent)
23Diabetes Mellitus, Type 2 - complications
24Diabetes Mellitus, Type 2 - drug therapy
25Diabetes therapy
26Docosahexaenoic acid
27Double-Blind Method
28Drug Therapy, Combination
29Eicosapentaenoic acid
30Endocrinology
31Endocrinology & Metabolism
32Endocrinology and Diabetes
33Endokrinologi och diabetes
34Fatty Acids - metabolism
35Fatty liver
36Female
37Fibroblast growth factor
38fish-oil
39glucose
40Glucose - metabolism
41Glucosides - administration & dosage
42growth-factor 21
43Hepatocytes - metabolism
44Human Physiology
45Humans
46Inflammation
47insulin sensitivity
48Internal Medicine
49Klinisk medicin
50Lipid Metabolism
51Liver diseases
52Liver Function Tests
53Liver steatosis
54Magnetic Resonance Imaging
55Male
56Medical and Health Sciences
57Medicin och hälsovetenskap
58Medicine
59Medicine & Public Health
60Metabolic Diseases
61Middle Aged
62Non
63Non-alcoholic fatty liver
64Non-alcoholic fatty liver disease
65Non-alcoholic Fatty Liver Disease - complications
66Non-alcoholic Fatty Liver Disease - drug therapy
67Omega
68Omega-3 fatty acids
69Organic acids
70oxidation
71Oxidative Stress
72pnpla3
73Proton density fat fraction
74resistance
75steatohepatitis
76Sweden
77Type 2 diabetes
78Unsaturated fatty acids
issn
00012-186X
11432-0428
21432-0428
fulltextfalse
rsrctypearticle
creationdate2018
recordtypearticle
recordideNp9k89u1DAQxiMEoqXwAFyQJS4cSLEd24k5VFqV8keq4FIhbpZjT1JXXjvEScvyRrwljra0bEVRDo7Gv-8be8ZTFM8JPiQY128SxoTyEpOmZKLmJX1Q7BNW0RIz2jws9pftkjTi217xJKULjHHFmXhc7FEpa8JpvV_8Ouk6MFNCsUNWD7r3rvPxpwtIB4tCWSGjxzb-2HhnkDbOZjKgEEOpvYnncQl3epo2yLtLGJF1CXQClA0GiIMHdOWmczRtBkA07-oWJkhvkUY2zq2HsvUuJxpztrjOWosGrw20sTQxTGP0PofSNNvN0-JRp32CZ9frQXH2_uTs-GN5-uXDp-PVaUlE00ylkIRJAww3RAppda1txWmrgUiJMZfcNoTXnTUMW8M17nBDCW9IA6QyRuKDotzapisY5lYNo1vrcaOidqqfB5VD_awSKCqkqBf-9b38O_d1peLYq3lWlWASk4wfbfHMrsEayJfUfke1uxPcuerjpRJYCkGWfJ-3BnGAoN0IO1obYFIWbD7oVady_5UU1ppKNxRzzahhFsuWk7arsYD8U2XDV9cnGuP3GdKkch8MeK8DxDkpigWjTArKM_ryDnoR5zHkbixULjPGrLmleu1BudDFfBGzmKoVZw3jmNOlEIf_oPJnYe1y76FzOb4jIFuBGWNKI3Q3FydYLeOgtuOg8jioZRzymQ6KF39X-0bx5_1noL5jatykJ7e8Pe38f63pdd-zaehhvK3F_aLfT64nyw
startdate20180703
enddate20180703
creator
0Eriksson, Jan W
1Lundkvist, Per
2Jansson, Per-Anders
3Johansson, Lars
4Kvarnström, Mats
5Moris, Linda
6Miliotis, Tasso
7Forsberg, Gun-Britt
8Risérus, Ulf
9Lind, Lars
10Oscarsson, Jan
general
0Springer Berlin Heidelberg
1Springer
2Springer Nature B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
93V.
107T5
117X7
127XB
1388E
148AO
158C1
168FI
178FJ
188FK
19ABUWG
20BENPR
21FYUFA
22GHDGH
23H94
24K9.
25M0S
26M1P
27PQEST
28PQQKQ
29PQUKI
30PRINS
317X8
32BOBZL
33CLFQK
345PM
35ADTPV
36AOWAS
37D8T
sort
creationdate20180703
titleEffects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
authorEriksson, Jan W ; Lundkvist, Per ; Jansson, Per-Anders ; Johansson, Lars ; Kvarnström, Mats ; Moris, Linda ; Miliotis, Tasso ; Forsberg, Gun-Britt ; Risérus, Ulf ; Lind, Lars ; Oscarsson, Jan
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1688t-69149ce4081969da7ad352bae19900595d8157fdc40dc5a0f08215818e13cc90
rsrctypearticles
prefilterarticles
languageeng
creationdate2018
topic
03 fatty acids
1adaptation
2Aged
3Alanine
4Alanine transaminase
5alcoholic fatty liver disease
6Analysis
7Article
8Aspartate aminotransferase
9Benzhydryl Compounds - administration & dosage
10Biomarkers
11Biomarkers - metabolism
12Body weight
13Carboxylic acids
14Carboxylic Acids - administration & dosage
15Clinical Medicine
16Clinical trials
17controlled-trial
18Cytokeratin
19Dapagliflozin
20Diabetes
21Diabetes mellitus
22Diabetes mellitus (non-insulin dependent)
23Diabetes Mellitus, Type 2 - complications
24Diabetes Mellitus, Type 2 - drug therapy
25Diabetes therapy
26Docosahexaenoic acid
27Double-Blind Method
28Drug Therapy, Combination
29Eicosapentaenoic acid
30Endocrinology
31Endocrinology & Metabolism
32Endocrinology and Diabetes
33Endokrinologi och diabetes
34Fatty Acids - metabolism
35Fatty liver
36Female
37Fibroblast growth factor
38fish-oil
39glucose
40Glucose - metabolism
41Glucosides - administration & dosage
42growth-factor 21
43Hepatocytes - metabolism
44Human Physiology
45Humans
46Inflammation
47insulin sensitivity
48Internal Medicine
49Klinisk medicin
50Lipid Metabolism
51Liver diseases
52Liver Function Tests
53Liver steatosis
54Magnetic Resonance Imaging
55Male
56Medical and Health Sciences
57Medicin och hälsovetenskap
58Medicine
59Medicine & Public Health
60Metabolic Diseases
61Middle Aged
62Non
63Non-alcoholic fatty liver
64Non-alcoholic fatty liver disease
65Non-alcoholic Fatty Liver Disease - complications
66Non-alcoholic Fatty Liver Disease - drug therapy
67Omega
68Omega-3 fatty acids
69Organic acids
70oxidation
71Oxidative Stress
72pnpla3
73Proton density fat fraction
74resistance
75steatohepatitis
76Sweden
77Type 2 diabetes
78Unsaturated fatty acids
toplevelpeer_reviewed
creatorcontrib
0Eriksson, Jan W
1Lundkvist, Per
2Jansson, Per-Anders
3Johansson, Lars
4Kvarnström, Mats
5Moris, Linda
6Miliotis, Tasso
7Forsberg, Gun-Britt
8Risérus, Ulf
9Lind, Lars
10Oscarsson, Jan
11Sahlgrenska akademin
12Institute of Medicine, Department of Molecular and Clinical Medicine
13Institutionen för medicin, avdelningen för molekylär och klinisk medicin
14Göteborgs universitet
15Gothenburg University
16Sahlgrenska Academy
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8ProQuest Central (Corporate)
9Immunology Abstracts
10Health & Medical Collection
11ProQuest Central (purchase pre-March 2016)
12Medical Database (Alumni Edition)
13ProQuest Pharma Collection
14Public Health Database
15Hospital Premium Collection
16Hospital Premium Collection (Alumni Edition)
17ProQuest Central (Alumni) (purchase pre-March 2016)
18ProQuest Central (Alumni Edition)
19ProQuest Central
20Health Research Premium Collection
21Health Research Premium Collection (Alumni)
22AIDS and Cancer Research Abstracts
23ProQuest Health & Medical Complete (Alumni)
24Health & Medical Collection (Alumni Edition)
25Medical Database
26ProQuest One Academic Eastern Edition
27ProQuest One Academic
28ProQuest One Academic UKI Edition
29ProQuest Central China
30MEDLINE - Academic
31OpenAIRE (Open Access)
32OpenAIRE
33PubMed Central (Full Participant titles)
34SwePub
35SwePub Articles
36SWEPUB Freely available online
jtitleDiabetologia
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Eriksson, Jan W
1Lundkvist, Per
2Jansson, Per-Anders
3Johansson, Lars
4Kvarnström, Mats
5Moris, Linda
6Miliotis, Tasso
7Forsberg, Gun-Britt
8Risérus, Ulf
9Lind, Lars
10Oscarsson, Jan
aucorp
0Sahlgrenska akademin
1Institute of Medicine, Department of Molecular and Clinical Medicine
2Institutionen för medicin, avdelningen för molekylär och klinisk medicin
3Göteborgs universitet
4Gothenburg University
5Sahlgrenska Academy
formatjournal
genrearticle
ristypeJOUR
atitleEffects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
jtitleDiabetologia
stitleDiabetologia
addtitleDiabetologia
date2018-07-03
risdate2018
volume61
issue9
spage1923
epage1934
pages1923-1934
issn
00012-186X
11432-0428
eissn1432-0428
abstractAims/hypothesis The EFFECT-II study aimed to investigate the effects of dapagliflozin and omega-3 ( n -3) carboxylic acids (OM-3CA), individually or combined, on liver fat content in individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Methods This randomised placebo-controlled double-blind parallel-group study was performed at five clinical research centres at university hospitals in Sweden. 84 participants with type 2 diabetes and NAFLD were randomly assigned 1:1:1:1 to four treatments by a centralised randomisation system, and all participants as well as investigators and staff involved in the study conduct and analyses were blinded to treatments. Each group received oral doses of one of the following: 10 mg dapagliflozin ( n  = 21), 4 g OM-3CA ( n  = 20), a combination of both ( n  = 22) or placebo ( n  = 21). The primary endpoint was liver fat content assessed by MRI (proton density fat fraction [PDFF]) and, in addition, total liver volume and markers of glucose and lipid metabolism as well as of hepatocyte injury and oxidative stress were assessed at baseline and after 12 weeks of treatment (completion of the trial). Results Participants had a mean age of 65.5 years (SD 5.9), BMI 31.2 kg/m 2 (3.5) and liver PDFF 18% (9.3). All active treatments significantly reduced liver PDFF from baseline, relative changes: OM-3CA, −15%; dapagliflozin, −13%; OM-3CA + dapagliflozin, −21%. Only the combination treatment reduced liver PDFF ( p  = 0.046) and total liver fat volume (relative change, −24%, p =  0.037) in comparison with placebo. There was an interaction between the PNPLA3 I148M polymorphism and change in liver PDFF in the active treatment groups ( p =  0.03). Dapagliflozin monotherapy, but not the combination with OM-3CA, reduced the levels of hepatocyte injury biomarkers, including alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase (γ-GT), cytokeratin (CK) 18-M30 and CK 18-M65 and plasma fibroblast growth factor 21 (FGF21). Changes in γ-GT correlated with changes in liver PDFF (ρ  =  0.53, p =  0.02). Dapagliflozin alone and in combination with OM-3CA improved glucose control and reduced body weight and abdominal fat volumes. Fatty acid oxidative stress biomarkers were not affected by treatments. There were no new or unexpected adverse events compared with previous studies with these treatments. Conclusions/interpretation Combined treatment with dapagliflozin and OM-3CA significantly reduced liver fat content. Dapagliflozin monotherapy reduced all measured hepatocyte injury biomarkers and FGF21, suggesting a disease-modifying effect in NAFLD. Trial registration: ClinicalTrials.gov NCT02279407 Funding: The study was funded by AstraZeneca.
copBerlin/Heidelberg
pubSpringer Berlin Heidelberg
pmid29971527
doi10.1007/s00125-018-4675-2
oafree_for_read